Arena Rises With Post-Belviq Pipeline

 
• By Mike Ward
  
Generate a summary of this article
Listen to this article
Beta

Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.

Video interview
Interview with Arena CEO Amit Munshi

Amit Munshi joined Arena Pharmaceuticals Inc. as CEO in 2016 to turn the company around. He negotiated the handing over of rights to the weight loss product Belviq (lorcaserin) to partner Eisai Co. Ltd. , and set about refocusing the business on its lead programs ralinepag and etrasimod. (Also see "Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates" - Scrip, 7 February, 2017.)

Cutting out costs of $100m and raising $270m from institutional investors, Arena saw its valuation rise from about $350m to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.